Top

BMC Psychiatry

Published in:

Open Access 01-12-2004 | Research article

S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

Authors: R Andrew Shippy, Douglas Mendez, Kristina Jones, Irene Cergnul, Stephen E Karpiak

Published in: BMC Psychiatry | Issue 1/2004

Abstract

Background

This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen.

Methods

The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e.

Results

Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments.

Conclusions

SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.

Available only for authorised users

Ciesla JA, Roberts JE: Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001, 158: 725-30. 10.1176/appi.ajp.158.5.725.CrossRefPubMed

Capaldini L, Harrison G: Overcoming Depression. BETA. 2004, 16 (2): 18-25.PubMed

Conwell Y, Brent D: Suicide and Aging. I: Patterns of Psychiatric Diagnosis. International Psychogeriatrics. 1995, 7 (2): 149-64. 10.1017/S1041610295001943.CrossRefPubMed

New York City Department of Health and Mental Hygiene: HIV Surveillance and Epidemiology Program Quarterly Report, 2(3). New York: New York City Department of Health and Mental Hygiene, Retrieved. 2004, August 16, 2004, [http://www.nyc.gov/html/doh/html/pub/pub.html]

Shippy RA, Karpiak SE: The Aging HIV/AIDS Population: Fragile Social Networks. Aging and Mental Health.

Reece M: HIV-related Mental Health Care: Factors Influencing Dropout among Low-income, HIV-positive Individuals. AIDS Care. 2003, 15: 707-716. 10.1080/09540120310001595195.CrossRefPubMed

Heckman TG, Kochman A, Sikkema KJ: Depressive symptoms in older adults living with HIV disease: Application of the chronic illness quality of life model. Journal of Mental Health & Aging. 2002, 8 (4): 267-279.

Risa KJ, Nepon L, Justis JC, Panwalker A, Berman SM, Cinti S, Wagener MM, Singh N: Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy. International Journal of STD & AIDS. 2002, 13 (10): 706-713. 10.1258/095646202760326471.CrossRef

Chesney M: Adherence to HAART regimens. AIDS Patient Care and STDs. 2003, 17 (4): 169-177. 10.1089/108729103321619773.CrossRefPubMed

10.

Inungu JN, Mokotoff ED, Kent JB: Characteristics of HIV infection in patients fifty years or older in Michigan. AIDS Patient Care & STDs. 2001, 15 (11): 567-573. 10.1089/108729101753287658.CrossRef

11.

Nichols JE, Speer D, Watson B, Watson M, Vergon T, Vallee C, Meah J: Aging with HIV: Psychological, Social, and Health Issues. 2002, San Diego: Academic Press

12.

Linsk NL: HIV among older adults: Age-specific issues in prevention and treatment. AIDS Reader. 2000, 10 (7): 430-440.PubMed

13.

Manfredi R: HIV disease and advanced age: An increasing therapeutic challenge. Drugs and Aging. 2002, 19 (9): 647-669.CrossRefPubMed

14.

Gatto G, Caleri D, Michelacci S, Sicuteri F: Analgesizing effect of a methyl donor (S-adenosylmethionine) in migraine: an open clinical trial. Int J Clin Pharmacol Res. 1986, 6: 15-17.PubMed

15.

Baldessarini RJ: Neuropharmacology of S-aenosyl-L-methionine. Am J Med. 1987, 83 (suppl 5A): 95-103. 10.1016/0002-9343(87)90860-6.CrossRefPubMed

16.

Lipinski JF, Cohen BM, Frankenburg F, Tohen M, Waternaux C, Altesman R, Jones B, Harris P: Open trial of S-adeosylmethionine for treatment of depression. Am J Psychiatry. 1984, 141: 448-450.CrossRefPubMed

17.

Kagan BL, Sultzer DL, Rosenlicht N, Gemer R: Oral S-adeonsylmethionine in depression: a randomized, double-blind placebo-controlled trial. Am J Psychiatry. 1990, 147: 591-595.CrossRefPubMed

18.

Bell KM, Plon L, Bunney WE, Potkin SG: S-adenosylmethionine in the treatment of depression: a controlled clinical trial. Am J Psychiatry. 1988, 145: 1110-1114.CrossRefPubMed

19.

Bressa GM: S-adenosylmethionine (SAM-e) as an antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994, 154: 7-14.CrossRefPubMed

20.

Di Rocco A, Rogers J, Brown R, Werner P, Bottiglieri T: S-Adenosyl-Methionine Improves Depression in Patients with Parkinson's Disease in an Open-Label Clinical Trial. Movement Disorders. 2000, 15: 1225-1229. 10.1002/1531-8257(200011)15:6<1225::AID-MDS1025>3.0.CO;2-A.CrossRefPubMed

21.

Tavoni A: Evaluation of S-adenosylmethionine in secondary fibromyalgia: A double-blind study. Clin Exp Rheumatol. 1998, 16: 106-7.PubMed

22.

Bottiglieri T, Ryland K: S-adenosylmethionine levels in psychiatric and neurological disorders: a review. Acta Neurol Scand Suppl. 1994, 154: 19-26.CrossRefPubMed

23.

Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV, Hahn SR, Brody D, Johnson JG: Utility of a New Procedure for Diagnosing Mental Disorders in Primary Care: The PRIME-MD 1000 Study. JAMA. 1994, 272: 1749-1756. 10.1001/jama.272.22.1749.CrossRefPubMed

24.

First MB, Spitzer RL, Gibbon M, Williams JB: Structured Clinical Interview for DSM-IV Axis I Disorders: Clinical Version. 1997, Washington, DC: American Psychiatric Association

25.

Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry. 1961, 4: 561-71.CrossRefPubMed

26.

Hamilton M: Development of a Rating Scale for Primary Depressive Illness. Brit J Soc Clin Psychology. 1967, 6: 278-296.CrossRef

27.

Burnam MA, Bing EG, Morton SC, Sherbourne C, Fleishman JA, London AS, Vitiello B, Stein M, Bozzette SA, Shapiro MF: Use of Mental Health and Substance Abuse Treatment Services among Adults with HIV in the United States. Arch Gen Psychiatry. 2001, 58: 729-736. 10.1001/archpsyc.58.8.729.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/4/38/prepub

Title: S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS
Authors: R Andrew Shippy
Douglas Mendez
Kristina Jones
Irene Cergnul
Stephen E Karpiak
Publication date: 01-12-2004
Publisher: BioMed Central
Published in: BMC Psychiatry / Issue 1/2004
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/1471-244X-4-38

Keynote webinar | Spotlight on medication adherence

Springer Medicine

S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2004

Social Phobia in an Italian region: do Italian studies show lower frequencies than community surveys conducted in other European countries?

A population-based study of anxiety as a precursor for depression in childhood and adolescence

Negative and positive childhood experiences across developmental periods in psychiatric patients with different diagnoses – an explorative study

Thyroid function in clinical subtypes of major depression: an exploratory study

The Bipolar Affective Disorder Dimension Scale (BADDS) – a dimensional scale for rating lifetime psychopathology in Bipolar spectrum disorders

Mental health first aid training of the public in a rural area: a cluster randomized trial [ISRCTN53887541]